Aerovate Therapeutics Inc (AVTE) - Total Liabilities
Based on the latest financial reports, Aerovate Therapeutics Inc (AVTE) has total liabilities worth $2.49 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check AVTE asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Aerovate Therapeutics Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Aerovate Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Aerovate Therapeutics Inc balance sheet assets.
Aerovate Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Aerovate Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hyundai Livart Furniture Co Ltd
KO:079430
|
Korea | ₩358.54 Billion |
|
Super Dragon Technology Co Ltd
TW:9955
|
Taiwan | NT$1.80 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩22.80 Billion |
|
PolyPid
NASDAQ:PYPD
|
USA | $11.33 Million |
|
Daemyung Sonoseason Co.Ltd
KQ:007720
|
Korea | ₩54.13 Billion |
|
Lifevantage Corporation
NASDAQ:LFVN
|
USA | $28.52 Million |
|
Asetek A/S
F:A31
|
Germany | €35.78 Million |
|
MAIA Biotechnology Inc.
NYSE MKT:MAIA
|
USA | $7.56 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Aerovate Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See AVTE equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 32.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aerovate Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aerovate Therapeutics Inc (2019–2024)
The table below shows the annual total liabilities of Aerovate Therapeutics Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.90 Million | -78.30% |
| 2023-12-31 | $17.96 Million | +109.89% |
| 2022-12-31 | $8.56 Million | +190.59% |
| 2021-12-31 | $2.94 Million | -83.69% |
| 2020-12-31 | $18.06 Million | +152.33% |
| 2019-12-31 | $7.16 Million | -- |
About Aerovate Therapeutics Inc
Aerovate Therapeutics, Inc., a biopharmaceutical company, engages in the treatment of pulmonary arterial hypertension in the United States. Aerovate Therapeutics, Inc., was incorporated in 2018 and is headquartered in Waltham, Massachusetts.